OCULAR HYPERTENSION TREATMENT STUDY (OHTS)

眼压过高治疗研究 (OHTS)

• 批准号: 2164302
• 负责人: REAY H BROWN
• 金额: $ 16.49万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1994
• 资助国家: 美国
• 起止时间: 1994-01-01 至 1998-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2164302
• 关键词: African American; beta antiadrenergic agent; carbachol; chemoprevention; clinical trials; cooperative study; disease /disorder proneness /risk; dosage; drug administration routes; drug adverse effect; early diagnosis; epinephrine; eye disorder chemotherapy; eye fundus photography; eye pharmacology; glaucoma; glaucoma test; human subject; human therapy evaluation; intraocular pressure; longitudinal human study; mass screening; medical complication; miotic; optic disk; pilocarpine; prognosis; statistics /biometry; therapy compliance; vision disorders; visual fields

DESCRIPTION (Investigator's Abstract) "This is an application to become a participating Clinical Center in the Ocular Hypertension Treatment Study (OHTS). The complete details of the OHTS rationale, design, and methods are contained in the OHTS Manual of Procedures. This proposal provides complete documentation of the ability of Dr. Reay H. Brown and his co-investigators to screen large numbers of ocular hypertensive patients and to enroll at least 50 eligible patients over a 24-month period. Documentation is provided of the capabilities of the proposed investigators and their staff for the performance of the study in accordance with the details of the OHTS Manual of Procedures and the nature and extent of their commitment to the department of Ophthalmology at Emory University. This application includes information on Dr. Brown and his two co-investigators who will follow patients screened for enrollment and randomization to treatment in the OHTS clinical trial."

描述（研究者的摘要） “这是成为参与临床中心的申请 眼高血压治疗研究（OHTS）。 完整的细节 OHTS理由，设计和方法包含在OHTS手册中 程序。 该提案提供了Reay H.博士的能力的完整文档。 布朗和他的共同投资者筛选大量眼 高血压患者，并至少在A上注册50名合格患者 24个月。 提供了拟议调查员的功能的文件 以及他们的工作人员根据 OHTS手册的细节以及其性质和范围 埃默里大学对眼科系的承诺。 这 申请包括有关布朗博士及其两个共同投资者的信息 谁将跟随筛查的患者进行入学和随机分组 在OHTS临床试验中进行治疗。”